Press Releases
Please find bellow all the press releases.
Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris.
2023
17/11/2023: Genomic Vision announces the opening of a receivership proceedings
14/11/2023: Financial Information for the third quarter of 2023
07/11/2023: Genomic Vision : communiqué relatif aux démissions au sein de la gouvernance (French version)
03/11/2023: Genomic Vision requests receivership proceedings
02/11/2023: Genomic Vision expands its Replication Combing Assay service offering
29/09/2023: Rapport financier du premier semestre au 30 juin 2023 (French version)
29/09/2023: First-Half 2023 Results
18/07/2023: Genomic Vision launches HexaCard, a new service for characterizing transformed cell lines
22/06/2023: Genomic Vision enters distribution agreement with CliniSciences
20/06/2023: Genomic Vision enters technology agreement with The Institute of Cancer Research, London
07/06/2023: Genomic Vision Provides Strategy Update
05/05/2023: Financial Information for the First Quarter of 2023
28/04/2023: Availability of the 2023 annual financial report French version
20/04/2023: 2022 Annuals Results
03/04/2023: Genomic Vision joins BioLead to advance innovation and production of biopharmaceuticals in France.
07/03/2023: Genomic Vision launches FiberSmart®, AI-powered software for automating genomic analysis
28/02/2023: Financial Information for the Fourth Quarter of 2022
13/01/2023: Bilan semestriel du contrat de liquidité contractée avec CM-CIC Securities. (French version)
05/01/2023: Genomic Vision annonces succesful Beta Testing of FiberSmart®
2022
22/12/2022: Our reflections on 2022 and what 2023 holds (Shareholders letter)
27/10/2022: Financial Information for the Third Quarter of 2022
24/10/2022: Genomic Vision: press release regarding changes in the Company’s governance
29/09/2022: First Half 2022 Results
22/07/2022: Financial information for the First Half of 2022
13/07/2022: Genomic Vision: changes in the Company’s governance
23/06/2022: Genomic Vision obtains the renewal of the ISO 13485: 2016 certification
05/05/2022: Financial Information for the First Quater of 2022.
28/04/2022: Availability of the 2021 annual financial report French version
21/04/2022: Financial information: Annual Results 2021
11/04/2022: New Financing Line with Winance, Subject to Prior Approval of the Company’s Shareholders
15/02/2022: Financial Information for the Fourth Quater of 2021
2021
24/12/2021: Financial information, 2 new tranches of convertible notes with warrants for 2M€
28/10/2021: Financial Information for the Third Quarter 2021
13/10/2021: Appointment of Thierry Huet as R&D Director
28/09/2021: Genomic Vision launches TeloSizer® for precise detection and quantitative measurement of telomere length
29/07/2021: First-half 2021 results
10/06/2021: 2nd call for OGM on June 30, 2021
17/05/2021: Financial Information for the First Quarter of 2021
14/05/2021: Partnership with SANOFI
29/04/2021: Financial information: Annual Results 2020
14/04/2021: Appointment of Mark David Lynch as Global Commercial and Marketing Director
18/02/2021: Financial Information for the Fourth Quarter of 2020
12/01/2021: French documentation “Bilan Semestriel du contrat de liquidité S2 2020”
2020
24/11/2020: Issuance of the first tranche of convertible notes with warrants (OCABSA)
12/11/2020: Financial Information for the Third Quarter of 2020
13/10/2020: Genomic Vision signs a distribution agreement for Covid-19 rapid diagnostic tests with Toda Pharma
29/09/2020: First Half Results
22/09/2020: Genomic Vision: convening of another Extraordinary General Meeting on October 30, 2020
24/07/2020: Genomic Vision: convening of a new Combined Shareholders’ Meeting on August 10, 2020
20/07/2020: Financial Information for the First Half of 2020
09/07/2020: Half-yearly balance of the Liquidity Agreement with CM-CIC Securities
06/07/2020: Press release on the availability of the 2019 annual financial report
06/07/2020: Press release on the availability of the preparatory documents for the AGM of 24 July 2020
29/05/2020: Financial information for the 1st quarter of 2020
21/05/2020: Financial information: FYR 2019
18/05/2020: Financial information : Drawdown of the 4th tranche
30/04/2020: Financial information
09/04/2020: Genomic Vision strenghtens its governance
13/02/2020: Dana Farber Cancer Institute adopts Genomic Vision’s platform including the FiberVisionS
11/02/2020: Financial information
30/01/2020: Q4 2019 Financial information
21/01/2020: Genomic Vision’s technology to be tested by the NIST
15/01/2020: Strategic Partnership between Genomic Vision and GIPTIS
2019
30/10/2019: Q3 2019 Financial information
21/10/2019: Promising results for the TLA assay
25/10/2019: Genomic Vision’s platform installed at the NIH
24/09/2019: Financial information for the First Half of 2019
26/07/2019: Financial information for the First Half of 2019: turnover and cash position
22/07/2019: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
09/07/2019: Genomic Vision reports of the Combined Shareholders’ Meeting of July 8, 2019
21/06/2019: Second convening of Shareholders meeting of July 8, 2019
02/05/2019: Financial information for the First Quarter of 2019
26/03/2019: Genomic Vision announces the signing of the financing contract with Winance
06/03/2019: 2018 Annual Results
18/02/2019: Genomic Vision: convening of another Extraordinary Shareholders’ Meeting on March 4, 2019
08/02/2019: Genomic Vision: Oxford University selects the molecular combing technology to study DNA replication in the context of a rare disease
06/02/2019: Financial information for the Fourth Quarter of 2018
11/01/2019: Bilan semestriel du contrat de liquidités contracté avec CM-CIC Securities (in French)
2018
22/11/2018: Genomic Vision signs a licensing agreement with Phyteneo on HPV integration test in Czech Republic
29/10/2018: Genomic Vision: positive results of the clinical study EXPL-HPV-002 in cervical cancer detection
24/10/2018: Financial information for the Third Quarter of 2018
28/09/2018: First Semester Financial Report 2018 (in French)
10/09/2018: Genomic Vision achieves second milestone with Quest Diagnostics on SMA carrier testing
06/08/2018: Genomic Vision: new perspectives in the genomic analysis of plants
25/07/2018: First half 2018 results
17/07/2018: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
05/07/2018: Genomic Vision provides an update on its commercial development and financial situation
19/06/2018: Compte rendu de l’assemblée générale mixte du 19 juin 2018 (in French)
02/05/2018: Genomic Vision invited to present molecular combing at Genopole
27/04/2018: Financial Information for the First Quarter of 2018
26/04/2018: Provision of the 2017 Financial Annual Report (in French only)
21/03/2018: 2017 Annual Results
14/03/2018: Genomic Vision extends its collaboration with Quest Diagnostics in spinal muscular atrophy (SMA)
17/01/2018: 2017 Annual revenue from sales: +36% to €2.1 million
04/01/2018: Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French only)
2017
24/10/2017: Financial information at Sept 30, 2017
18/10/2017: Genomic Vision: report of the LSR R&D Day on october 16, 2017
03/10/2017: Genomic Vision hosts 2nd R&D day on october 16th in Paris
13/09/2017: High attendance at the first US satellite symposium on molecular combing
25/07/2017: First half 2017 results
26/07/2017: Genomic Vision launches its online store “GV Store”
20/06/2017: Compte rendu de l’assemblée générale mixte du 20 juin 2017 (in French)
19/06/2017: Genomic Vision inks Chinese distribution deal with APG Bio Ltd
30/05/2017: Genomic Vision declares its eligibility to the French tax regime PEA-PME for 2017/2018 (in French only)
22/05/2017: Genomic Vision to enter into technological collaboration with AstraZeneca in oncology
15/05/2017: Report of the IVD R&D Day of 10 May 2017
10/05/2017: Genomic Vision announces promising preliminary results for its clinical study in cervical cancer detection
09/05/2017: Financial information at March 31, 2017
20/04/2017: Genomic Vision hosts inaugural R&D day with its long-standing partner Quest Diagnostics
29/03/2017: Issuance of all the warrants for convertible notes with warrants (BEOCABSA)
01/03/2017: 2016 annual results in line with the successful execution of the new strategy in LSR market
09/01/2017: Financial information at December 31st, 2016
2016
26/07/2016: Results for the first half of 2016
11/07/2016: Genomic Vision launches EasyScan, the first digital service for analyzing DNA by molecular combing
16/06/2016: The clinical trial led by Genomic Vision and Reims University Hospital presented at the Eurogin Congress
09/05/2016: Financial information at March 31, 2016
23/03/2016: New strategic development area
22/03/2016: 2015 Annual Results
17/03/2016: Genomic Vision obtains NF EN ISO 13485:2012 quality certification
10/03/2016: Genomic Vision’s DNA analysis technology singled out in a study published by Nature
08/02/2016: Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
04/02/2016: 2016 Financial Calendar
18/01/2016: 2015 sales in line with expectations after all planned milestones with Quest Diagnostics were met
11/01/2016: Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments
2015
01/12/2015: GENOMIC VISION to Present at the LD Micro Main Event
12/11/2015: GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
22/10/2015: Revenue from 3rd quarter activity up 47%
31/07/2015: 2015 first-half results in line with company expectations
09/06/2015: Genomic Vision selected for the Horizon 2020 program’s ‘BeyondSeq’ project with a total grant of €6 million
06/05/2015: Financial information of the 31st of March 2015 (French)
30/04/2015: 2014 Financial Report available (French)
31/03/2015: Genomic Vision reaffirms its eligibility for the PEA-SME status for 2015/2016 (French)
17/02/2015: Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years
09/02/2015: Financial Agenda 2015
15/01/2015: 2014 Annual Revenue from Sales at €3.5 Million